



FOR IMMEDIATE RELEASE
Thursday, November 8, 2001

CONTACT: Dr. Floyd E. Bloom
Chief Executive Officer
(858) 677-0466

**NEUROME, INC. ANNOUNCES DR. LESLIE IVERSEN AS SECOND SCIENTIFIC
ADVISORY BOARD MEMBER**

LA JOLLA, CA – Neurome, Inc. announced today the appointment of Leslie Iversen, Ph.D., as the second member of its Scientific Advisory Board. Dr. Iversen, Professor of Pharmacology at the Royal Postgraduate Medical School, Hammersmith Hospital in London and Visiting Professor in the Department of Pharmacology at the University of Oxford, is internationally recognized for his fundamental contributions to the understanding of neurotransmission and has linked his findings to the treatment and diagnosis of schizophrenia and Alzheimer's disease. He presently serves as Director of the Wolfson Centre for Age-Related Diseases at King's College in London.

"Leslie Iversen's discoveries of the actions of amino acid, neuropeptide and classical neurotransmitters have been the pioneering foundation for the discovery and development of many medications," said Dr. Floyd Bloom, Neurome's chief executive officer. "He brings the kind of wisdom that Neurome needs to interpret the discoveries that we hope to make in our research program. We are delighted to have Dr. Iversen join Tomas Hökfelt on our Scientific Advisory Board."

Dr. Iversen's principal areas of study include neurotransmitter and neuropeptide mechanisms in the mammalian central nervous system and the discovery and development of novel neuropharmacological agents.

"I welcome this opportunity to join Floyd Bloom, John Morrison and Warren Young as they focus the Neurome Technologies to document, for the post-genome, the molecular structure of the brain," said Iversen. "Their impressive new platform will make possible a new generation of functional exploration and understanding."

Dr. Iversen received his Ph.D. and B.A. from the University of Cambridge. He was previously Vice President of Neuroscience Research at Merck Research Laboratories and was Director of the Neuroscience Research Center of Merck, Sharpe and Dohme in the UK from 1983-1995. He was the Director of the Medical Research Council, Neurochemical Pharmacology Unit in Cambridge, England from 1970-1983. More recently, Dr. Iversen founded Panos Therapeutics, where he serves as Director. Earlier this year, the General Board at the University of Oxford reconfirmed Dr. Iversen's title as Visiting Professor in Pharmacology through 2003.

Dr. Iversen is a recipient of numerous awards, including Fellow of the Royal Society of London and Foreign Associate Member of the National Academy of Sciences in the United States. He is the author of over 350 scientific publications.

Neurome, Inc. develops standardized, quantitative databases that accurately depict and integrate gene expression patterns in the three-dimensional context of the brain's structures, circuits and cells, and deploys these databases in primary research directed toward the discovery and development of gene targets for enhancement of brain function and treatment of brain-based disease. Neurome performs contract brain research for pharmaceutical and biotechnology companies, while at the same time pursuing its own in-house and collaborative research protocols. The data collected from these efforts will populate an evolving, comprehensive database available by subscription and useful on a broad level for analyses of mouse models of brain function and disease. In this regard, the application of the Neurome technologies will provide rigorous, quantitative data that are optimally suited to the measurement of subtle cell-type specific shifts in gene expression, as well as progression and prevention of degenerative events affecting specific cell classes and brain regions.

For more information, please contact Neurome, Inc., 11149 North Torrey Pines Road, La Jolla, California 92037-1031. Telephone: (858) 677-0466; Fax (858) 677-0458; Web site: www.neurome.com.

###